Lupin drops after weak Q4 outcome

Lupin lost 1.44% to Rs 1,724 at 14:45 IST on BSE after consolidated net profit fell 1.08% to Rs 547.01 crore on 0.97% decline in total income to Rs 3095.35 crore in Q4 March 2015 over Q4 March 2014.

The Q4 result was announced during market hours today, 13 May 2015.

Meanwhile, the S&P BSE Sensex was up 332.57 points or 1.24% at 27,210.05.

On BSE, so far 2.41 lakh shares were traded in the counter as against average daily volume of 82.771 shares in the past one quarter.

The stock was volatile. The stock fell as much as 2.6% at the day's low of Rs 1,703.75 so far during the day. The stock rose as much as 3.07% at the day's high of Rs 1,803 so far during the day. The stock had hit a record high of Rs 2,112 on 8 April 2015. The stock had hit a 52-week low of Rs 903.95 on 27 May 2014.

The stock had underperformed the market over the past one month till 12 May 2015, sliding 10.96% compared with Sensex's 6.93% fall. The scrip had, however, outperformed the market in past one quarter, surging 7.99% as against Sensex's 6.69% fall.

The large-cap company has equity capital of Rs 89.96 crore. Face value per share is Rs 2.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations as well as biotechnology product and APIs globally.

Powered by Capital Market - Live News